drugset / Trial / NCT01868516

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

NCT01868516

Phase 2 Completed 1635 enrolled Targacept Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.

Timeline

Start
2013-05
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject dexmecamylamine Other / unclassified 0.5 mg Oral
Subject dexmecamylamine Other / unclassified 1 mg Oral
Subject dexmecamylamine Other / unclassified 2 mg Oral

Indications